Benitec Biopharma (BNTC) AI Stock Analysis

• Market Cap: $334.43M
• Dividend Yield: N/A
• Average Volume (3M): 164.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: -100.00%
• EPS Growth: 83.98%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 26,250,470
• 10 Day Avg. Volume: 375,727
• 30 Day Avg. Volume: 164,161
• PEG Ratio: <0.01
• Price to Book (P/B): 55.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.62
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 518.60
• Enterprise Value/Gross Profit: -102.58
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: $22.67
• Price Target Upside: 72.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 42 Neutral
• Price Target: $12.00 ▼(-8.88%Downside)

The overall stock score reflects significant financial instability and negative valuation metrics. Technical analysis indicates bearish momentum, further weighing on the stock's outlook. The absence of earnings call data and corporate events does not impact the score.

Positive Factors

Clinical Trials

Benitec Biopharma has made steady advances with the Phase 1b/2a trial of its lead clinical candidate, BB-301, with the sixth subject being safely treated with the low dose.

Financial Performance

Benitec Biopharma recorded a F3Q25 net loss of only $0.24 per share vs. the forecast of a net loss of $0.36 per share.

Regulatory Pathway

Analysts see a straightforward path to an approvable profile for BB-301 in oculopharyngeal muscular dystrophy, where current treatment options are limited and invasive.

Negative Factors

Clinical Trial Risks

Risks include slower-than-expected progress in the ongoing clinical trial of BB-301 and the potential for emergence of unexpected side effects.

Trial Data Limitations

The small number of patients in the trial limits the robustness of the data, and further evidence is needed to confirm a dose-response relationship.

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma (BNTC) is a biotechnology company focused on developing therapeutic solutions using its proprietary DNA-directed RNA interference (ddRNAi) technology. This technology aims to silence disease-causing genes, offering a novel approach to treating a range of genetic disorders. The company's core focus areas include orphan diseases, infectious diseases, and oncology.

How the Company Makes Money

Benitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary

Benitec Biopharma shows financial instability with significant losses and negative cash flow. The income statement reveals declining revenue, significant net losses, and negative margins. The balance sheet is strong with a high equity ratio and low leverage, but ongoing net losses reflected in the negative return on equity are concerning. Despite a robust cash position, the cash flow statement highlights negative operating and free cash flow, indicating high cash burn without substantial revenue improvement.

Income Statement

The income statement shows a declining revenue trend with a significant net loss and negative margins. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of -2916.67%, a net profit margin of -356916.67%, and an EBIT margin of -401550%. Revenue growth is inconsistent, showing a decline compared to previous periods, reflecting challenges in generating sales.

Balance Sheet

Benitec Biopharma's balance sheet shows a strong equity position with an equity ratio of 96.11% in TTM. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage. The return on equity is negative, reflecting ongoing net losses. The company maintains a robust cash position, providing some stability.

Cash Flow

The cash flow statement highlights negative operating cash flow and free cash flow in TTM. The free cash flow growth rate is negative, indicating cash burn. However, the company raised substantial financing, improving liquidity. The operating cash flow to net income ratio is close to 1, suggesting cash flow issues align with net losses.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	216.00K	75.00K	73.00K	59.00K	97.00K
Gross Profit	-91.00K	108.00K	-306.00K	64.00K	-64.00K	-171.06K
EBITDA	-29.94M	-22.49M	-18.70M	-17.85M	-13.60M	-7.91M
Net Income	-26.49M	-21.75M	-19.56M	-18.56M	-13.78M	-8.30M
Balance Sheet
Total Assets	105.21M	52.21M	4.46M	5.97M	21.38M	11.59M
Cash, Cash Equivalents and Short-Term Investments	103.58M	50.87M	2.48M	4.06M	19.77M	9.80M
Total Debt	959.00K	284.00K	559.00K	811.00K	213.00K	405.00K
Total Liabilities	7.64M	4.96M	4.26M	3.09M	1.37M	1.35M
Stockholders Equity	97.57M	47.25M	202.00K	2.88M	20.01M	10.24M
Cash Flow
Free Cash Flow	-18.69M	-19.58M	-18.01M	-15.91M	-13.05M	-7.63M
Operating Cash Flow	-18.67M	-19.40M	-18.01M	-15.90M	-12.83M	-7.54M
Investing Cash Flow	-18.00K	-179.00K	-1.00K	-13.00K	-221.00K	-94.00K
Financing Cash Flow	108.01M	68.03M	16.02M	0.00	22.52M	1.77M

Benitec Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Neutral. The current price of 13.17 is below the 20-day moving average (MA) of 14.47, below the 50-day MA of 14.27, and above the 200-day MA of 12.10, indicating a neutral trend. The MACD of -0.64 indicates Positive momentum. The RSI at 44.15 is Neutral, neither overbought nor oversold. The STOCH value of 37.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BNTC.

Benitec Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	58 Neutral	$387.51M	―	-22.95%	―	40.88%	-579.73%
AMLX	58 Neutral	$585.66M	―	-83.24%	―	-100.32%	-197.69%
PHAT	54 Neutral	$622.74M	―	181.41%	―	3055.71%	-18.80%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
ZBIO	42 Neutral	$427.55M	―	-115.47%	―	―	―
BNTC	42 Neutral	$334.43M	―	-48.57%	―	-100.00%	83.98%

Benitec Biopharma Corporate Events

Benitec Biopharma Announces Positive Interim Results for BB-301

On March 19, 2025, Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a study, presented at the 2025 Muscular Dystrophy Association Conference. The study showed significant improvements in swallowing function for three subjects with Oculopharyngeal Muscular Dystrophy (OPMD), achieving clinically normal swallowing profiles and reducing dysphagic symptom burdens. These results highlight the potential of BB-301 as a promising treatment for OPMD, a condition with limited therapeutic options, and may enhance Benitec’s position in the gene therapy market.